26 June 2024 - Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in both the EU and in the US.

Bavarian Nordic today announced the submission of a marketing authorisation application to the EMA seeking approval of the Company’s vaccine candidate for immunisation to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application was granted accelerated assessment by the CHMP in February 2024, supporting the potential approval of the vaccine by the European Commission in the first half of 2025.

Read Bavarian Nordic press release